 Increase in revenue of 166.9 million observed with FDA approved DMD drugs in Q3 of 2021; year over year increase of 37. Next-generation PPMO drugs are being advanced in order to improve upon the first generation types; in addition, other mutations observed in DMD are being targeted as well. 